Lilly completes acquisition of morphic to improve outcomes and expand options for people living with inflammatory bowel disease

Broadens lilly's immunology pipeline with morphic's oral integrin therapies, including morf-057 reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology indianapolis , aug. 16, 2024 /prnewswire/ -- eli lilly and company (nyse: lly) today announced the successful completion of its acquisition of morphic holding, inc. (nasdaq: morf). morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of Α4Β7 integrin (known as morf-057) for inflammatory bowel disease (ibd).
MORF Ratings Summary
MORF Quant Ranking